Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Akero Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOUTH SAN FRANCISCO, CALIF., AUG. 28, 2025 (GLOBE NEWSWIRE) -- AKERO THERAPEUTICS,INC.(NASDAQ: AKRO), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIONAL TREATMENTS FOR PATIENTS WITH SERIOUS METABOLIC DISEASES MARKED BY HIGH UNMET MEDICAL NEED, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE ON MONDAY, SEPTEMBER 8, 2025, AT 10:45 A.M. E.T. IN NEW YORK, NY.

AKERO THERAPEUTICS TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE

RESULTS SUPPORT POTENTIAL OF EFRUXIFERMIN (EFX) TO REDUCE RISK OF FIBROSIS PROGRESSION INPATIENTS WITH PRE-CIRRHOTIC (F2-F3) MASH RESULTS SUPPORT POTENTIAL OF EFRUXIFERMIN (EFX) TO REDUCE RISK OF FIBROSIS PROGRESSION INPATIENTS WITH PRE-CIRRHOTIC (F2-F3) MASH

AKERO THERAPEUTICS ANNOUNCES LANCET PUBLICATION OF THE PHASE 2B HARMONY CLINICAL TRIAL DEMONSTRATING 96 WEEKS TREATMENT WITH EFX REDUCED LIVER FIBROSIS IN PATIENTS WITH PRE-CIRRHOTIC MASH

PUBLISHED RESULTS FROM THE 96-WEEK PHASE 2B SYMMETRY TRIAL IN THE NEW ENGLAND JOURNAL OF MEDICINE THREE PRESENTATIONS AT THE EASL CONGRESS 2025 HIGHLIGHTED DATA DEMONSTRATING STATISTICALLY SIGNIFICANT REVERSAL OF COMPENSATED CIRRHOSIS (F4) DUE TO MASH AND CORROBORATING THE ANTI-FIBROTIC ACTIVITY OF EFX SEEN IN PATIENTS WITH PRE-CIRRHOTIC (F2-F3) MASH CASH, CASH EQUIVALENTS AND SHORT AND LONG-TERM MARKETABLE SECURITIES OF $1,086.2 MILLION AT JUNE 30, 2025 SOUTH SAN FRANCISCO,CALIF., AUG. 08, 2025 (GLOBE NEWSWIRE) -- AKERO THERAPEUTICS, INC. (NASDAQ: AKRO), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIONAL TREATMENTS FOR PATIENTS WITH SERIOUS METABOLIC DISEASES MARKED BY HIGH UNMET MEDICAL NEED, TODAY REPORTED SECOND QUARTER FINANCIAL RESULTS FOR THE PERIOD ENDING JUNE 30, 2025, AND PROVIDED BUSINESS UPDATES.

AKERO THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SOUTH SAN FRANCISCO, CALIF., JUNE 03, 2025 (GLOBE NEWSWIRE) -- AKERO THERAPEUTICS,INC.(NASDAQ: AKRO), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIONAL TREATMENTS FOR PATIENTS WITH SERIOUS METABOLIC DISEASES MARKED BY HIGH UNMET MEDICAL NEED, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, JUNE 10, 2025, AT 2:40 P.M. E.T.

AKERO THERAPEUTICS TO PRESENT AT THE GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

SOUTH SAN FRANCISCO, CALIF., MAY 28, 2025 (GLOBE NEWSWIRE) -- AKERO THERAPEUTICS,INC.(NASDAQ: AKRO), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIONAL TREATMENTS FOR PATIENTS WITH SERIOUS METABOLIC DISEASES MARKED BY HIGH UNMET MEDICAL NEED, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, JUNE 4, 2025, AT 8:45 A.M.

AKERO THERAPEUTICS TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

PHASE 2B SYMMETRY STUDY PRELIMINARY RESULTS SHOWED STATISTICALLY SIGNIFICANT REVERSAL OF COMPENSATED CIRRHOSIS (F4) DUE TO MASH FOLLOWING 96 WEEKS OF TREATMENT WITH EFRUXIFERMIN (EFX)

AKERO THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ANALYSIS OF EFX RESULTS WITH AI-BASED DIGITAL PATHOLOGY UNDERSCORES THE POTENTIAL VALUE IN EVALUATING HISTOPATHOLOGY RESPONSE

AKERO THERAPEUTICS AND HISTOINDEX PRESENT NEW ANALYSES OF PHASE 2B HARMONY TRIAL IN ORAL AND POSTER PRESENTATIONS AT THE EASL CONGRESS 2025

SOUTH SAN FRANCISCO, CALIF., MAY 09, 2025 (GLOBE NEWSWIRE) -- AKERO THERAPEUTICS, INC. (NASDAQ: AKRO), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIONAL TREATMENTS FOR PATIENTS WITH SERIOUS METABOLIC DISEASES MARKED BY HIGH UNMET MEDICAL NEED, PRESENTED RESULTS FROM THE PHASE 2B SYMMETRY TRIAL DEMONSTRATING THE POTENTIAL OF EFRUXIFERMIN (EFX) TOIMPROVE FIBROSIS IN COMPENSATED CIRRHOSIS (F4) CAUSED BY METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), IN A LATE-BREAKING ORAL PRESENTATION AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (EASL) CONGRESS 2025 TAKING PLACE MAY 7-10, IN AMSTERDAM, THE NETHERLANDS.

AKERO THERAPEUTICS PRESENTS WEEK 96 RESULTS FROM PHASE 2B SYMMETRY CLINICAL TRIAL OF EFRUXIFERMIN IN PATIENTS WITH COMPENSATED CIRRHOSIS CAUSED BY MASH SHOWING FIBROSIS IMPROVEMENT WITHOUT WORSENING OF MASH AT THE EASL CONGRESS 2025

RESULTS SUPPORT POTENTIAL BENEFIT OF EFRUXIFERMIN (EFX) TO ELICIT FIBROSIS IMPROVEMENT IN PATIENTS WITH COMPENSATED CIRRHOSIS (F4 FIBROSIS) DUE TO MASH 96-WEEK DATA FROM SYMMETRY TRIAL PRESENTED AT EASL CONGRESS 2025

Akero Therapeutics, Inc.

AKRO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Akero Therapeutics, Inc.

AKRO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AKRO